NCT04566952 (ANLOLA) is a Phase 2 clinical trial of Anlotinib in Ovarian Cancer, sponsored by Xiaoxiang Chen.

Who is sponsoring NCT04566952?

NCT04566952 is sponsored by Xiaoxiang Chen.

What drugs are being tested in NCT04566952?

Interventions in NCT04566952: Anlotinib, Olaparib.

What condition does NCT04566952 study?

NCT04566952 studies Ovarian Cancer, Ovarian and Fallopian Tube Cysts and Neoplasms, Neoplasms by Site, Neoplasms, Genital Neoplasms, Female, Urogenital Neoplasms, Neoplasms, Glandular and Epithelial, Neoplasms by Histologic Type, Carcinoma, Ovarian Epithelial, Ovarian Diseases, Adnexal Diseases, Genital Diseases, Female, Carcinoma, Anlotinib, PARP Inhibitors, BRCA1 Mutation, Angiogenesis, Antineoplastic Agents, BRCA2 Mutation.

Is NCT04566952 still recruiting?

NCT04566952 is currently status unknown. Last updated 30 October 2020.

Last reviewed 2020-10-30 · How we verify

NCT04566952: ANLOLA

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Anlotinib Combined With Dose-reduced Olaparib in Patients With Platinum-Sensitive Recurrent Ovarian Cancer

Status unknown Phase 2 Last updated 30 October 2020

What this trial tests

Phase 2 trial testing Anlotinib in Ovarian Cancer in 68 participants. Status unknown.

Timeline

28 October 2020

Primary endpoint
1 March 2023

1 October 2023

Quick facts

Lead sponsor	Xiaoxiang Chen
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	68
Start date	28 October 2020
Primary completion	1 March 2023
Estimated completion	1 October 2023
Sites	1 location across China

Drugs / interventions tested

Anlotinib — full drug profile →
Olaparib (olaparib) — full drug profile →

Conditions studied

Ovarian Cancer — all drugs for Ovarian Cancer →
Ovarian and Fallopian Tube Cysts and Neoplasms — all drugs for Ovarian and Fallopian Tube Cysts and Neoplasms →
Neoplasms by Site — all drugs for Neoplasms by Site →
Neoplasms — all drugs for Neoplasms →

Sponsor

Xiaoxiang Chen — full company profile →

Who can join

18 and older, female only, with Ovarian Cancer or Ovarian and Fallopian Tube Cysts and Neoplasms. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

PARP inhibitors have changed the treatment paradigm of ovarian cancer. Most patients using PARP(poly-ADP ribose polymerase) inhibitors will suffer different grades of adverse events(AEs), followed by dose reduction. It has not been reported whether the dose-reduced olaparib as maintenance treatment have an impact on efficacy. Both PAOLA-1 and AVANOVA 2 studies showed that combined PARP inhibitors and antiangiogenic drugs have synergistic anti-tumor effect. Anlotinib is a novel multi-target tyrosine kinase inhibitor that can inhibit VEGFR(vascular endothelial growth factor receptor), FGFR(fibroblast growth factor receptor), PDGFR(platelet-derived growth factor receptor) α/β, c-Kit, and Ret. And anlotinib has been approved as orphan drug designations for treatment of ovarian cancer by FDA in 2015. Previous studies showed that anlotinib had manageable toxicity and promising antitumor effect. Our study is expected to investigate the efficacy and safety of anlotinib combined with dose-reduced olaparib as maintenance treatment in platinum-sensitive recurrent ovarian cancer patients.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Anti-Angiogenic Therapy: Current Challenges and Future Perspectives.
Lopes-Coelho F, Martins F, Pereira SA, Serpa J. · · 2021 · cited 254× · PMID 33916438 · DOI 10.3390/ijms22073765
Targeting DNA repair pathway in cancer: Mechanisms and clinical application.
Wang M, Chen S, Ao D. · · 2021 · cited 84× · PMID 34977872 · DOI 10.1002/mco2.103
Clinical application of PARP inhibitors in ovarian cancer: from molecular mechanisms to the current status.
Wu Y, Xu S, Cheng S, Yang J, et al · · 2023 · cited 43× · PMID 36611214 · DOI 10.1186/s13048-023-01094-5
Strategies in Overcoming Homologous Recombination Proficiency and PARP Inhibitor Resistance.
Goel N, Foxall ME, Scalise CB, Wall JA, et al · · 2021 · cited 26× · PMID 34172532 · DOI 10.1158/1535-7163.mct-20-0992
Kinase Inhibitors in the Treatment of Ovarian Cancer: Current State and Future Promises.
Skorda A, Bay ML, Hautaniemi S, Lahtinen A, et al · · 2022 · cited 24× · PMID 36551745 · DOI 10.3390/cancers14246257
BRCA Mutations-The Achilles Heel of Breast, Ovarian and Other Epithelial Cancers.
Loboda AP, Adonin LS, Zvereva SD, Guschin DY, et al · · 2023 · cited 18× · PMID 36902416 · DOI 10.3390/ijms24054982
Role of tumor microenvironment in ovarian cancer metastasis and clinical advancements.
Wang Y, Zhu N, Liu J, Chen F, et al · · 2025 · cited 15× · PMID 40369674 · DOI 10.1186/s12967-025-06508-0
Efficacy and Safety of PARP Inhibitor Combination Therapy in Recurrent Ovarian Cancer: A Systematic Review and Meta-Analysis.
Ren N, Zhang L, Yu J, Guan S, et al · · 2021 · cited 12× · PMID 34485111 · DOI 10.3389/fonc.2021.638295

Verify or expand the search:

Other trials of Anlotinib

Trials testing the same drug.

NCT07470840 — SBRT Plus Anlotinib and Bimepolizumab in Locally Advanced or Metastatic Renal Cell Carcinoma · Phase 2 · not yet recruiting
NCT07537777 — Benmelstobart Plus Anlotinib Combined With SBRT for Patients With Hepatocellular Carcinoma Failing First-Line Targeted T · Phase 2 · not yet recruiting
NCT07320963 — Chidamide in Combination With Toripalimab and Anlotinib in Recurrent/Metastatic Nasopharyngeal Carcinoma. · Phase 1, PHASE2 · not yet recruiting
NCT07388875 — Sacituzumab Tirumotecan Plus Anlotinib in Previously Treated ES-SCLC · Phase 2 · not yet recruiting
NCT07376499 — Prospective, Single-arm, Phase II Clinical Study of Irinotecan Hydrochloride Liposome Injection Combined With Platinum a · Phase 2 · not yet recruiting

Other recruiting trials for Ovarian Cancer

Currently open trials in the same condition.

NCT06412120 — Study Evaluating Safety, Tolerability, and Metabolism of Niraparib · Phase 4 · recruiting
NCT06930755 — Study of NMS-03305293 in Adult Patients With Relapsed Ovarian Cancer · Phase 1 · recruiting
NCT07318558 — A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021) · Phase 3 · recruiting
NCT07491081 — EARLY Study: Evaluating the Specificity and Feasibility of the EARLY Biomarker Panel for Ovarian Cancer Detection · NA · recruiting
NCT07410676 — EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors · Phase 1, PHASE2 · recruiting

Other Xiaoxiang Chen trials

Trials by the same sponsor.

NCT04556071 — Efficacy and Safety of Niraparib Combined With Bevacizumab in Platinum Refractory/Resistant Recurrent Ovarian Cancer · Phase 2 · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04566952 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Xiaoxiang Chen
Last refreshed: 30 October 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04566952.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing